Steven M. Opal, MD; Pierre-Francois Laterre, MD; Bruno Francois, MD; et al.
In a randomized, double-blind, placebo-controlled, multinational phase 3 trial in 197 intensive care units (1961 patients), Opal and coauthors explored whether eritoran, a TLR4 antagonist, significantly reduced sepsis-induced mortality.